title: Pharmacogenetic angiogenesis profiling for first-line chemotherapy in patients with advanced gastric cancer.
abstract: We retrospectively investigated germline polymorphisms in angiogenesis pathway genes (14 SNPs) and their correlation to clinical outcome (progression free survival and overall survival) in 128 patients with unresectable-advanced gastric carcinoma (AGC) treated with first-line chemotherapy. Our analysis revealed that Endostatin +4349 G>A polymorphism exhibited a worse progression free survival (PFS) and overall survival (OS) compared with the GG genotype. Significant OS difference was also observed in the endothelial nitric oxide synthase (eNOS)-786 T>C polymorphism. Hence, common germline variants in Endostatin and eNOS genes have predictive significance for clinical outcome and survivality in AGC patients treated with first-line chemotherapy.
authors: Department of Oncology, Chinese PLA General Hospital, Postgraduate Medical School, Beijing, China.
authors: Su
authors: S
authors: Dan
authors: Li
authors: L
authors: Bai
authors: Wang
authors: W
authors: Li-Jie
authors: Zhang
authors: Z
authors: Ting
authors: Mao
authors: M
authors: Zhi-Yuan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D043169:Endostatins / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009389:Neovascularization, Pathologic / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology
chemical_list: D043169:Endostatins; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III